Your browser doesn't support javascript.
Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic.
Levey, Natalie H; Forrest, Alexandra D; Spielman, Daniella W; Easley, Kirk A; Dude, Carolynn M; Badell, Martina L.
  • Levey NH; Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA (Drs Levey, Forrest, Spielman, Dude, and Badell). Electronic address: natalie.levey@emory.edu.
  • Forrest AD; Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA (Drs Levey, Forrest, Spielman, Dude, and Badell).
  • Spielman DW; Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA (Drs Levey, Forrest, Spielman, Dude, and Badell).
  • Easley KA; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA (Mr Easley).
  • Dude CM; Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA (Drs Levey, Forrest, Spielman, Dude, and Badell).
  • Badell ML; Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA (Drs Levey, Forrest, Spielman, Dude, and Badell).
Am J Obstet Gynecol MFM ; 4(5): 100673, 2022 09.
Article in English | MEDLINE | ID: covidwho-1878042
ABSTRACT

BACKGROUND:

Pregnant patients with SARS-CoV-2 infection are at increased risk for severe disease including hospitalization, intensive care admission, ventilatory support, and death. Although pregnant patients were excluded from investigational trials for pharmacologic treatments for COVID-19 illness, the National Institutes of Health treatment guidelines state that efficacious treatments should not be withheld from pregnant patients. An infusion of casirivimab and imdevimab (REGEN-COV), a monoclonal antibody therapy, was shown to reduce the risk of COVID-19-related hospitalization or death from any cause and resolved symptoms and reduced SARS-CoV-2 viral load more rapidly than placebo. In July of 2021, the Food and Drug Administration released an Emergency Use Authorization for REGEN-COV. Although pregnant persons were not included in the original trials, given the higher risk of morbidity and mortality in the pregnant population, our institution offered REGEN-COV to our pregnant patients beginning in August of 2021. Side effects after REGEN-COV administration are rare and thought to be secondary to COVID-19 rather than REGEN-COV.

OBJECTIVE:

This study aimed to track safety and clinical outcomes in unvaccinated pregnant patients who received REGEN-COV and to compare these outcomes with those of a contemporary cohort of patients who tested positive for SARS-CoV-2 and were eligible but did not receive REGEN-COV. Our hypothesis was that REGEN-COV administration during pregnancy is safe, and that pregnant persons who received REGEN-COV would experience less severe COVID-19 respiratory illness, with decreased length of hospital stay, rates of intensive care unit admission, and need for oxygen and other COVID-19 therapeutics. STUDY

DESIGN:

This is a retrospective cohort study of pregnant patients who either tested positive for SARS-CoV-2 or had a known exposure to a COVID-19-positive person, and were therefore eligible for REGEN-COV at our institution. Within this cohort, we compared those who received REGEN-COV with those who did not between March and October of 2021 at Grady Memorial Hospital in Atlanta, Georgia. The main outcomes studied were perinatal outcomes, safety data, and the clinical course of SARS-CoV-2 infection.

RESULTS:

From March to October of 2021, 86 pregnant people tested positive for SARS-CoV-2 via real-time polymerase chain reaction or had a confirmed exposure. In this group, 36 received REGEN-COV and 50 did not. There were no instances of infusion rate adjustment or discontinuation, anaphylaxis, or death among individuals who received REGEN-COV. One individual experienced worsening shortness of breath >24 hours after administration, which was classified as an infusion-related reaction. There were no significant differences in perinatal outcomes, length of hospitalization, rates of intensive care unit admission, additional pharmacologic treatment for COVID-19, or oxygen requirement between the 2 groups.

CONCLUSION:

Administration of REGEN-COV is safe in pregnancy and did not increase adverse maternal, neonatal, or obstetrical outcomes. There was not a statistically significant difference in COVID-19-related outcomes in our high-risk population. Given the likely safety of this drug in pregnancy and its known benefits in the nonpregnant population, we advocate for the continued use of this therapy and encourage the development of future studies to enroll a larger and more diverse cohort to explore its efficacy further.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Infant, Newborn / Pregnancy Country/Region as subject: North America Language: English Journal: Am J Obstet Gynecol MFM Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Female / Humans / Infant, Newborn / Pregnancy Country/Region as subject: North America Language: English Journal: Am J Obstet Gynecol MFM Year: 2022 Document Type: Article